Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
92.29
+0.10 (0.11%)
At close: Feb 27, 2026, 4:00 PM EST
92.55
+0.26 (0.28%)
After-hours: Feb 27, 2026, 7:39 PM EST
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts that cover Mirum Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $108.92, which forecasts a 18.02% increase in the stock price over the next year. The lowest target is $72 and the highest is $132.
Price Target: $108.92 (+18.02%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mirum Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Buy | 5 | 6 | 6 | 6 | 6 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 11 | 11 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $120 → $118 | Buy | Maintains | $120 → $118 | +27.86% | Feb 26, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $115 → $117 | Strong Buy | Maintains | $115 → $117 | +26.77% | Feb 26, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $130 → $128 | Buy | Maintains | $130 → $128 | +38.69% | Feb 26, 2026 |
| Citizens | Citizens | Buy Maintains $140 → $132 | Buy | Maintains | $140 → $132 | +43.03% | Feb 26, 2026 |
| Stifel | Stifel | Strong Buy Maintains $98 → $125 | Strong Buy | Maintains | $98 → $125 | +35.44% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
651.13M
from 521.31M
Increased by 24.90%
Revenue Next Year
780.49M
from 651.13M
Increased by 19.87%
EPS This Year
-0.12
from -0.47
EPS Next Year
0.54
from -0.12
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 692.6M | 885.2M | |||
| Avg | 651.1M | 780.5M | |||
| Low | 567.4M | 695.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 32.9% | 35.9% | |||
| Avg | 24.9% | 19.9% | |||
| Low | 8.8% | 6.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.26 | 2.68 | |||
| Avg | -0.12 | 0.54 | |||
| Low | -1.44 | -0.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.